EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH

View source ↗

Summary

Qaialdo is a spironolactone product by Lipomed GmbH that has been authorized in the EU. Indications include edema, heart failure, liver cirrhosis with ascites, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Edema
• Essential Hypertension
• Heart Failure
• Hyperaldosteronism
• Liver Cirrhosis
• Nephrotic Syndrome

Drugs mentioned

• Qaialdo (spironolactone)

Snippet

Status: Authorised. Therapeutic area: Edema;Heart Failure;Liver Cirrhosis;Ascites;Nephrotic Syndrome;Hyperaldosteronism;Essential Hypertension. MAH: Lipomed GmbH. Decision date: 24/03/2026